For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Vitamin D + Fish Oil Placebo | Vitamin D: Vitamin D3 (cholecalciferol), 2000 IU per day Fish oil placebo: Fish oil placebo, one capsule per day | 153 | None | 545 | 4573 | 2803 | 4573 | View |
| Vitamin D Placebo + Fish Oil | Vitamin D placebo: Vitamin D3 placebo, one capsule per day Fish oil: Omacor, one capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]) | 152 | None | 569 | 4563 | 2789 | 4563 | View |
| Vitamin D + Fish Oil | Vitamin D: Vitamin D3 (cholecalciferol), 2000 IU per day Fish oil: Omacor, one capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]) | 153 | None | 549 | 4608 | 2825 | 4608 | View |
| Vitamin D Placebo + Fish Oil Placebo | Vitamin D placebo: Vitamin D3 placebo, one capsule per day Fish oil placebo: Fish oil placebo, one capsule per day | 133 | None | 570 | 4609 | 2876 | 4609 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Major cardiovascular event | SYSTEMATIC_ASSESSMENT | Vascular disorders | None | View |
| Invasive cancer of any type | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | None | View |
| Gastrointestinal Bleeding | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Hypercalcemia | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Suicide | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Hyperparathyroidism or parathyroid condition | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Kidney stones | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Kidney failure | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Hematuria | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Easy bruising | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Frequent nosebleeds | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Stomach upset or pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Skin rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |